Company Name Navitor Pharmaceuticals
Mailing Address 1030 Massachusetts Avenue Cambridge, MA 02138 USA
Company Description New scientific insights are emerging regarding the primal signaling pathways that direct an organism’s metabolic response to conditions in its environment—such as dynamic changes in the availability of nutrients, energy, oxygen and other factors—and the role of these metabolic signaling pathways in disease.
Proceeds Purposes The Series B funding will enable Navitor to advance a lead program into clinical trials with the objective of demonstrating initial efficacy and safety. The company will also continue to develop additional pipeline candidates and augment its proprietary drug discovery platform.
Venture Investor Brace Pharma
Venture Investor Remeditex Ventures
Venture Investor Sanofi-Genzyme BioVentures
Venture Investor Polaris Partners
Venture Investor Accomplice
Venture Investor SR One
Venture Investor Johnson & Johnson Development Corporation